Affitech A/S announced that the U.S. Patent and Trademark Office (USPTO) has granted Affitech U.S. patent (no. 8,034,905) covering the Company’s anti-VEGF antibody drug candidate AT001/r84. The newly granted US patent is the first patent grant Affitech has received for this compound in a major territory and it considerably strengthens Affitech's IP position regarding this drug candidate. The patent is co-owned by Affitech and its collaboration partner Peregrine Pharmaceuticals.
Commenting on the new patent, Managing Director of Affitech A/S Martin Welschof said: “The grant of the patent on AT001/r84 by the USPTO is pleasant news. We hereby extend our patent portfolio for AT001/r84 to include USA, which is important for the further development of this antibody drug candidate. The development of AT001/r84 is progressing well and IBC Generium expects to commence the first phase 1 clinical trial with the drug candidate before year end 2011.”
AT001/r84 is a proprietary therapeutic antibody to vascular endothelial growth factor (VEGF) being developed by Affitech and IBC Generium as a potential alternative to bevacizumab (Avastin®) for the treatment of certain human cancers. The Russian health authorities have identified cancer therapy based on anti-VEGF antibodies as one of the top priority areas of pharma-innovation in Russia. Affitech’s AT001/r84 has the potential to satisfy patient needs in this area. The rights to develop and commercialize AT001/r84 outside Russia and the CIS remain with Affitech.